Dr Hiren Mandaliya is a fellow of The Royal Australasian College of Physicians. Dr Mandaliya also has an interest in cancer research.

Following attainment of his fellowship, Dr Mandaliya joined Calvary Mater Newcastle as Clinical Trial Fellow in 2018 to broaden his research experience.  He has been involved in multiple Phase I, Phase II, Phase III and investigator initiated trials as an investigator. He works with leading clinicians, scientists and researchers in the field. Since 2019, he has been appointed as staff specialist medical oncologist at Calvary Mater Newcastle.

Dr Mandaliya has a broad interest in the management of malignancies such as gastrointestinal, gynaecological, genitourinary, lung, melanoma, breast and head & neck.

Dr Mandaliya is a regular member of the multidisciplinary tumour board meeting at John Hunter Hospital and Calvary Mater Newcastle.

Dr Mandaliya completed his MBBS and MD (Internal Medicine) in India and came to Australia in 2009. He completed his fellowship training in Medical Oncology (FRACP) at Calvary Mater Newcastle, North West Cancer Centre (Tamworth) and Macarthur Cancer Therapy Centre.

Currently he has been involved with various research projects with scientists at Calvary Mater Newcastle, University of Newcastle and Hunter Medical Research Institute. Dr Mandaliya has a strong commitment to medical education and is affiliated as a Conjoint lecturer with the University of Newcastle. He is also an active member of Future Leaders Group of Hunter Cancer Research Alliance (HCRA).

Dr Mandaliya has conducted research projects for breast, lung, gastrointestinal and other malignancies. His research work and interests have also focused on psychosocial aspects of cancer survivors and medical students’ education. He has presented his research results at various local, national and international conferences such as ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology). Dr Mandaliya has also published his research in various peer-reviewed journals.

He is a member of Medical Oncology Group of Australia (MOGA), the Australasian Gastro-Intestinal Trials Group (AGITG), Breast Cancer Trials group, ASCO and ESMO.